Zhitong Finance APP News, Hengrui Pharmaceutical (600276megawaysmonopoly.SH) issued an announcement that SHR-A1921 for injection from the company's subsidiary Suzhou Shengdiya Biomedicine Co., Ltd. was proposed to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration, with a publicity period of 7 days. Proposed indications (or functions) for this drugmegawaysmonopoly: Used for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
